Zhong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zhong Wang has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Qing Li
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
10 shared publications Changhua Zhou
School of Pharmaceutical Sciences Sun Yat‐Sen University Guangzhou China
5 shared publicationsJiayu Liu
School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China
4 shared publications- Wei Xie
MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory for Biocontrol, School of Life Sciences, Sun Yat-Sen University, Guangzhou, Guangdong, 510006, People's Republic of China
4 shared publications Yanlan Wang
School of Pharmaceutical Sciences Sun Yat‐Sen University Guangzhou China
4 shared publicationsChunnian Wang
Shanghai Institute for Advanced Immunochemical Studies Shanghai Tech University Shanghai China
3 shared publications
Latest Publications
- Open Access
Strongly interacting multi-solitons for generalized Benjamin-Ono equations
We consider the generalized Benjamin-Ono equation: $$\partial_tu+\partial_x(-|D|u+|u|^{p-1}u)=0,$$ with $L^2$-supercritical power $p>3$ or $L^2$-subcritical power $2<p3$.Open AccessStrongly interacting multi-solitons for generalized Benjamin-Ono equations
We consider the generalized Benjamin-Ono equation: $$\partial_tu+\partial_x(-|D|u+|u|^{p-1}u)=0,$$ with $L^2$-supercritical power $p>3$ or $L^2$-subcritical power $2<p3$. - 22 January 2021
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 110 (1) , 229-237
A Novel AKR1C3 Specific Prodrug TH3424 With Potent Antitumor Activity in Liver Cancer
Overexpression of AKR1C3, an aldo‐keto reductase, was recently discovered in liver cancers. In this study, an inverse correlation between AKR1C3 expression and liver cancer patient survival was observed. AKR1C3 inhibitors, however, failed to suppress liver cancer cell growth. The prodrug TH3424, which releases a DNA alkylating reagent upon reduction by AKR1C3, was developed to target tumors with overexpression of AKR1C3. TH3424 showed specific killing of liver cancer cells with AKR1C3 overexpression both in vitro and in vivo. In patient‐derived mouse xenograft models, TH3424 at doses as low as 1.5 mg/kg eliminated liver tumors with no apparent toxicity. Conclusion: TH3424 is a promising drug candidate for liver cancer and other types of cancers overexpressing AKR1C3.
- 22 January 2021
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 110 (1) , 229-237
A Novel AKR1C3 Specific Prodrug TH3424 With Potent Antitumor Activity in Liver Cancer
Overexpression of AKR1C3, an aldo‐keto reductase, was recently discovered in liver cancers. In this study, an inverse correlation between AKR1C3 expression and liver cancer patient survival was observed. AKR1C3 inhibitors, however, failed to suppress liver cancer cell growth. The prodrug TH3424, which releases a DNA alkylating reagent upon reduction by AKR1C3, was developed to target tumors with overexpression of AKR1C3. TH3424 showed specific killing of liver cancer cells with AKR1C3 overexpression both in vitro and in vivo. In patient‐derived mouse xenograft models, TH3424 at doses as low as 1.5 mg/kg eliminated liver tumors with no apparent toxicity. Conclusion: TH3424 is a promising drug candidate for liver cancer and other types of cancers overexpressing AKR1C3.
- 24 February 2020
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 61 (7) , 1660-1668
An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL
AKR1C3 overexpression has been reported in various types of cancers, including T-ALL. AST-006 (TH-3424), an AKR1C3-specific prodrug, was reported recently to have potent cytotoxicity against liver cancer cells overexpressing AKR1C3 and T-ALL. In this study, AST-006 demonstrated potent anti-tumor activity against different T-ALL cell lines in vitro and in vivo, including patient-derived xenograft (PDX) model. AST-006 also exhibited minimal cytotoxicity against primary human T-cells in vitro and lymphocytes in cynomolgus monkeys in vivo, indicating that AST-006 is a promising therapeutic for T-ALL.
- 24 February 2020
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 61 (7) , 1660-1668
An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL
AKR1C3 overexpression has been reported in various types of cancers, including T-ALL. AST-006 (TH-3424), an AKR1C3-specific prodrug, was reported recently to have potent cytotoxicity against liver cancer cells overexpressing AKR1C3 and T-ALL. In this study, AST-006 demonstrated potent anti-tumor activity against different T-ALL cell lines in vitro and in vivo, including patient-derived xenograft (PDX) model. AST-006 also exhibited minimal cytotoxicity against primary human T-cells in vitro and lymphocytes in cynomolgus monkeys in vivo, indicating that AST-006 is a promising therapeutic for T-ALL.
- Open Access
- 29 September 2019
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 21 (1) , 72-80
Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies
CD16a (FcγRIIIa) mediates the antibody dependent cellular cytotoxicity (ADCC) and is important for anti-tumor activities of many therapeutic antibodies. Bispecific antibody targeting natural killer (NK) cells has been studied for cancer therapy. In this work, anti-CD16a single-domain antibodies were identified from hCD16a immunized camel. Bispecific antibodies are then constructed by fusing these single domain antibodies with an anti-CEA single domain antibody. These bispecific antibodies can recruite NK cells to kill CEA-positive tumor cells, and inhibit tumor growth in vivo, suggesting that these anti-CD16a single domain antibodies are powerful tools to engaging NK cells for cancer therapy.
- 29 September 2019
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 21 (1) , 72-80
Open AccessIdentification of anti-CD16a single domain antibodies and their application in bispecific antibodies
CD16a (FcγRIIIa) mediates the antibody dependent cellular cytotoxicity (ADCC) and is important for anti-tumor activities of many therapeutic antibodies. Bispecific antibody targeting natural killer (NK) cells has been studied for cancer therapy. In this work, anti-CD16a single-domain antibodies were identified from hCD16a immunized camel. Bispecific antibodies are then constructed by fusing these single domain antibodies with an anti-CEA single domain antibody. These bispecific antibodies can recruite NK cells to kill CEA-positive tumor cells, and inhibit tumor growth in vivo, suggesting that these anti-CD16a single domain antibodies are powerful tools to engaging NK cells for cancer therapy.
- Open Access
- 1 September 2019
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 14, 66-73
Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities
- 1 September 2019
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 14, 66-73
Open AccessBp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities
- 12 July 2018
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 137
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
A Gpc3-targeting Bispecific Antibody Gpc3-s-fab With Potent Cytotoxicity. JoVE publishes peer-reviewed scientific video protocols to accelerate biological, medical, chemical and physical research. Watch our scientific video articles. JoVE is the world-leading producer and provider of science videos with the mission to improve scientific research, scientific journals, and education. Millions of scientists, educators and students at thousands of universities, colleges, hospitals and biopharmaceutical companies worldwide use JoVE for their research, teaching and learning.
- 12 July 2018
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 137
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
A Gpc3-targeting Bispecific Antibody Gpc3-s-fab With Potent Cytotoxicity. JoVE publishes peer-reviewed scientific video protocols to accelerate biological, medical, chemical and physical research. Watch our scientific video articles. JoVE is the world-leading producer and provider of science videos with the mission to improve scientific research, scientific journals, and education. Millions of scientists, educators and students at thousands of universities, colleges, hospitals and biopharmaceutical companies worldwide use JoVE for their research, teaching and learning.
- Open Access
- 11 May 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (1) , 1259-1266
A HER2 bispecific antibody can be efficiently expressed in Escherichia�coli with potent cytotoxicity
Bispecific antibodies have been actively studied for cancer therapy due to their potent cytotoxicity against tumor cells. A number of bispecific antibody formats have exhibited strong tumor cytotoxicity in vitro and in vivo. However, effective production of bispecific antibodies remains challenging for the majority of bispecific antibody formats. In the present study, a bispecific antibody was designed that links a conventional antigen-binding fragment (Fab) against cluster of differentiation 3 antigen (CD3) to a camel single domain antibody (VHH) against human epidermal growth factor receptor 2 (HER2). This bispecific antibody may be secreted and purified efficiently from Escherichia coli culture medium. The purified bispecific antibody is able to trigger T cell-mediated HER2-specific cytotoxicity in vitro and in vivo. The data gathered in the present study suggest that this bispecific format may be applied to other tumor antigens to produce bispecific antibodies more efficiently.
- 11 May 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (1) , 1259-1266
Open AccessA HER2 bispecific antibody can be efficiently expressed in Escherichia�coli with potent cytotoxicity
Bispecific antibodies have been actively studied for cancer therapy due to their potent cytotoxicity against tumor cells. A number of bispecific antibody formats have exhibited strong tumor cytotoxicity in vitro and in vivo. However, effective production of bispecific antibodies remains challenging for the majority of bispecific antibody formats. In the present study, a bispecific antibody was designed that links a conventional antigen-binding fragment (Fab) against cluster of differentiation 3 antigen (CD3) to a camel single domain antibody (VHH) against human epidermal growth factor receptor 2 (HER2). This bispecific antibody may be secreted and purified efficiently from Escherichia coli culture medium. The purified bispecific antibody is able to trigger T cell-mediated HER2-specific cytotoxicity in vitro and in vivo. The data gathered in the present study suggest that this bispecific format may be applied to other tumor antigens to produce bispecific antibodies more efficiently.
- Open Access
- 1 May 2018
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 13, 3189-3201
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
Introduction: Bispecific antibodies that engage immune cells to kill cancer cells are actively pursued in cancer immunotherapy. Different types of bispecific antibodies, including single-chain fragments, Fab fragments, nanobodies, and immunoglobulin Gs (IgGs), have been studied. However, the low molecular weight of bispecific antibodies with single-chain or Fab fragments generally leads to their rapid clearance in vivo, which limits the therapeutic potential of these bispecific antibodies. Materials and methods: In this study, we used a site-specific PEGylation strategy to modify the bispecific single-domain antibody-linked Fab (S-Fab), which was designed by linking an anticarcinoembryonic antigen (anti-CEA) nanobody with an anti-CD3 Fab. Results: The half-life (t1/2) of PEGylated S-Fab (polyethylene glycol-S-Fab) was increased 12-fold in vivo with a slightly decreased tumor cell cytotoxicity in vitro as well as more potent tumor growth inhibition in vivo compared to S-Fab. Conclusion: This study demonstrated that PEGylation is an effective approach to enhance the antitumor efficacy of bispecific antibodies.
- 1 May 2018
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 13, 3189-3201
Open AccessSite-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
Introduction: Bispecific antibodies that engage immune cells to kill cancer cells are actively pursued in cancer immunotherapy. Different types of bispecific antibodies, including single-chain fragments, Fab fragments, nanobodies, and immunoglobulin Gs (IgGs), have been studied. However, the low molecular weight of bispecific antibodies with single-chain or Fab fragments generally leads to their rapid clearance in vivo, which limits the therapeutic potential of these bispecific antibodies. Materials and methods: In this study, we used a site-specific PEGylation strategy to modify the bispecific single-domain antibody-linked Fab (S-Fab), which was designed by linking an anticarcinoembryonic antigen (anti-CEA) nanobody with an anti-CD3 Fab. Results: The half-life (t1/2) of PEGylated S-Fab (polyethylene glycol-S-Fab) was increased 12-fold in vivo with a slightly decreased tumor cell cytotoxicity in vitro as well as more potent tumor growth inhibition in vivo compared to S-Fab. Conclusion: This study demonstrated that PEGylation is an effective approach to enhance the antitumor efficacy of bispecific antibodies.
- Open Access
- 1 April 2018
- Published by Elsevier in Translational Oncology
- Vol. 11 (2) , 366-373
A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities
- 1 April 2018
- Published by Elsevier in Translational Oncology
- Vol. 11 (2) , 366-373
Open AccessA Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities